



April 06, 2018

**FROM :** Schulman IRB ("Schulman" or the "Board")  
**TO:** All sites that receive Schulman approval to conduct this protocol  
**SUBJECT:** Recruitment/Study-Related Material  
**IRB NO.:** 201705400;  
**SPONSOR :** Shire Human Genetic Therapies, Inc.  
**PROTOCOL NO.:** SHP647-302

The following item was reviewed by Expedited Review, as referenced below, and received a decision of

**Approved for use ONLY in its entirety**

**Material Type :** Other

**Description :** 10862379\_Shire\_IBD\_302\_DTP\_Flyer

**Material Item# :** MA1804538-0

**Review Date :** 04/05/2018

Approved and/or Acknowledged Recruitment/Study-Related materials should not be used or distributed to study subjects until you have received an approval letter from Schulman to conduct this study.

Acknowledged material includes, but is not limited to, copyrighted documents, some subject instructions, standardized questionnaires, etc.

Any variation of approved or acknowledged materials must be resubmitted as outlined in the Recruitment Guidance available at [www.sairb.com](http://www.sairb.com).

PLEASE REFERENCE MATERIAL ITEM NUMBER **MA1804538-0** ON ALL CORRESPONDENCE

**WebPortal/Paperless**



\* 6 0 - M A 1 8 0 4 5 3 8 - 1 - 7 \*

# UC GOES EVERYWHERE WITH YOU.



## What is the study about?

FIGARO 302 is a clinical research study designed to explore an investigational drug—SHP647—for participants with moderate-to-severe ulcerative colitis (UC) who have responded inadequately to conventional treatment.

Learn more about UC and the FIGARO study. Speak to your doctor today or visit [www.MyUCStudy.com](http://www.MyUCStudy.com) or [www.MyUCandCrohns.com](http://www.MyUCandCrohns.com).

